Answers are grounded in this paper and cite their sources.
Retrospective observational study assesses seizure reduction and safety of CBD in children with epilepsy, indicating positive outcomes.
Aim: The primary objective was to assess seizure frequency before and after initiation of cannabidiol (CBD) therapy and to evaluate percentage seizure reduction following CBD treatment. The secondary objective was to evaluate adverse drug reactions associated with CBD use and to analyze duration of CBD therapy among patients. Materials and Methods: A retrospective observational study was conducted in patients with epilepsy receiving CBD therapy at Amrita Institute of Medical Sciences in the Department of Pediatric Neurology. Data was collected from patient medical records and follow-up documentation. Variables collected included demographic details, seizure frequency before and after initiation of CBD therapy, duration of CBD treatment, and adverse drug reactions (ADRs). Percentage seizure reduction was calculated for each patient and categorized based on possible treatment response. Statistical analysis was performed using Microsoft Excel. Seizure frequency before and after CBD therapy was compared using Wilcoxon signed-rank test. A p -value of < 0.000153 was considered statistically significant. Results: A total of 32 children, females = 11 (34.37%) and males = 21 (65.62%), receiving CBD therapy in epilepsy were included in the study. The mean age at initiation of CBD therapy was 7.40+ or –6.07 years. Among the study population, 28.10% patients achieved > 50% seizure reduction, while 15.60% patients achieved > 75% seizure reduction. ADRs were observed 18.75% patients, with most common ADRs being excessive sedation, tiredness, and few with increased frequency of seizures. The mean duration of CBD was 12.3+ or –8.5 months. Conclusion: CBD therapy demonstrated highly statistically significant reduction in seizure frequency among patients with epilepsy. CBD therapy was generally well tolerated, with manageable ADRs. These findings support the effectiveness and safety of CBD as an adjunctive therapy option in epilepsy management. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: